ofatumumab + chlorambucil

**Ofatumumab + chlorambucil** is a combination therapy used in the treatment of previously untreated chronic lymphocytic leukemia (CLL) in patients for whom fludarabine-based therapy is considered inappropriate due to age or comorbidities[2][1][3][4]. Ofatumumab is a fully human monoclonal antibody that targets the CD20 molecule on B lymphocytes, leading to cell lysis through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity[2]. Chlorambucil is an oral alkylating agent (a nitrogen mustard) that causes DNA cross-linking and subsequent cell death[1][2]. The combination has demonstrated improved progression-free survival compared to chlorambucil alone, with a manageable safety profile and clinically important outcomes for patients with limited therapeutic options[1][2][3][4].

Other names

ofatumumab and chlorambucilofatumumab plus chlorambucil